How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

219 results for

(statistics OR statistical OR data OR demography OR demographics OR demography) AND "National Institute of Arthritis and Musculoskeletal and Skin Disease"

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Musculoskeletal Research at the National Institute of Arthritis and Musculoskeletal and Skin Diseases: A Snapshot (PubMed)

of Health, Building 31, Room 4C32, 31 Center Drive, Bethesda, MD 20892, USA. katzs@od.niams.nih.gov eng Journal Article United States J Bone Joint Surg Am 0014030 0021-9355 AIM IM Communication Humans National Institute of Arthritis and Musculoskeletal and Skin Diseases (U.S.) statistics & numerical data Research statistics & numerical data United States 2009 2 3 9 0 2009 2 3 9 0 2009 2 24 9 0 ppublish 19181994 91/2/474 10.2106/JBJS.H.01607 PMC2657312 (...) Musculoskeletal Research at the National Institute of Arthritis and Musculoskeletal and Skin Diseases: A Snapshot 19181994 2009 02 23 2016 05 12 1535-1386 91 2 2009 Feb The Journal of bone and joint surgery. American volume J Bone Joint Surg Am Musculoskeletal research at the National Institute of Arthritis and Musculoskeletal and Skin Diseases: a snapshot. 474-5 10.2106/JBJS.H.01607 Katz Stephen I SI National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes

Full Text available with Trip Pro

2009 The Journal of Bone and Joint Surgery. American volume.

2. Increasing prevalence of knee pain and symptomatic knee osteoarthritis: survey and cohort data. (PubMed)

Foundation and National Institutes of Health. The FOA Study was funded by the National Heart, Lung, and Blood Institute (for the parent Framingham Heart Study), National Institute on Aging, and National Institute of Arthritis and Musculoskeletal and Skin Diseases (FOA Study), National Institutes of Health. (...) Increasing prevalence of knee pain and symptomatic knee osteoarthritis: survey and cohort data. A recent surge in knee replacements is assumed to be due to aging and increased obesity of the U.S. population.To assess whether age, obesity, and change in radiographic knee osteoarthritis explain the trend in knee pain and osteoarthritis.Cross-sectional, using data from 6 NHANES (National Health and Nutrition Examination Survey) surveys between 1971 and 2004 and from 3 examination periods

Full Text available with Trip Pro

2011 Annals of Internal Medicine

3. Low Back Pain, Adult Acute and Subacute

of corticosteroids • Trauma with neurological signs Note: There is not sufficient data on a history of osteoporosis as a specific risk factor. Infection An uncommon but serious cause for back pain is infection. A spinal infection such as vertebral osteomyelitis or spinal epidural abscess can present as back pain with a fever. Consideration of other non-spine origins Low back pain can be due to visceral disease. Examples include (Goldman, 2011): • Disease of pelvic organs (prostatitis, endometriosis, chronic (...) was associated with better effects on function; effects on pain favored manipulation but were small and statistically insignificant. There were no differences between spinal manipulation and inert treat - ment in pain relief at one week, but better longer-term pain relief is possible. There were no differences in function at one week or three months. There was no difference between spinal manipulation versus other active interventions in pain relief at one week, one month, three to six months or one year

2018 Institute for Clinical Systems Improvement

4. Treatment of Osteoarthritis of the Knee: An Update Review

Lester, Ph.D. * National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institutes of Health Bethesda, MD Jyme Schafer, M.D., M.P.H. Centers for Medicare & Medicaid Services Baltimore, MD iv Neil Segal, M.D.* Dr. George Varghese Professor of Rehabilitation Medicine Department of Rehabilitation Medicine University of Kansas Medical Center Kansas City, KS *Provided input on Draft Report. Peer Reviewers Prior to publication of the final evidence report, EPCs sought input from (...) electrical stimulation [TENS], neuromuscular electrical stimulation, and pulsed electromagnetic field therapy [PEMF]); whole body vibration; heat, infrared, or ultrasound; orthoses (knee braces, shoe inserts, or specially designed shoes); weight loss diets; and home-based therapy or self-management. Data sources. PubMed ® , Embase ® , the Cochrane Collection, Web of Science, and the Physiotherapy Evidence Database (PEDRO) from 2006 to September 2016, and ClinicalTrials.gov and the proceedings from

2017 Effective Health Care Program (AHRQ)

5. Diagnosis and Treatment of Low Back Pain

is not intended to serve as a standard of care. Standards of care are determined on the basis of all clinical data available for an individual patient and are subject to change as scientific knowledge and technology advance and patterns evolve. This CPG is based on evidence available through October 2016 and is intended to provide a general guide to best practices. The guideline can assist healthcare providers, but the use of a CPG must always be considered as a recommendation, within the context (...) and collect qualitative data on a thoughtfully predetermined set of questions. Therefore, as part of the effort to update this CPG, VA and DoD Leadership, along with the LBP CPG Work Group, held a patient focus group prior to finalizing the KQs for the evidence review. The group met on September 7, 2016, at the William Beaumont Army Medical Center in El Paso, Texas. The aim of the focus VA/DoD Clinical Practice Guideline for Diagnosis and Treatment of Low Back Pain September 2017 Page 17 of 110 group

2017 VA/DoD Clinical Practice Guidelines

6. National Institutes of Health Pathways to Prevention Workshop: Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention. (PubMed)

the field. The workshop was cosponsored by the NIH Office of Disease Prevention (ODP), National Institute of Arthritis and Musculoskeletal and Skin Diseases, and National Institute on Aging. A multidisciplinary working group developed the agenda, and an Evidence-based Practice Center prepared an evidence report through a contract with the Agency for Healthcare Research and Quality to facilitate the discussion. During the 1.5-day workshop, invited experts discussed the body of evidence and attendees had (...) the opportunity to comment during open discussions. After data from the evidence report, expert presentations, and public comments were weighed, an unbiased independent panel prepared a draft report that was posted on the ODP Web site for 5 weeks for public comment. This final report summarizes the panel's findings and recommendations. Current gaps in knowledge are highlighted, and a set of recommendations for new, strengthened research to better inform the long-term use of osteoporotic drug therapies

Full Text available with Trip Pro

2019 Annals of Internal Medicine

7. Axial Spondyloarthritis

- culoskeletalandSkinDiseases,NIH. 1 Michael M. Ward, MD, MPH, Robert A. Colbert, MD, PhD: National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland; 2 Atul Deodhar, MD, Jayme Hiratzka, MD: Oregon Health & Science University, Portland; 3 Elie A. Akl, MD, MPH, PhD: American University of Beirut, Beirut, Lebanon, and McMaster University, Hamilton, Ontario, Canada; 4 AndrewLui,PT,DPT,LianneS.Gensler,MD:UniversityofCalifornia, San Francisco; 5 Joerg Ermann, MD: Brigham and Women’s Hospital (...) , and/or honoraria from Abbott and UCB(lessthan$10,000each). Address correspondence to Michael M. Ward, MD, MPH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Building 10 CRC, Room 4-1339, 10 Center Drive, Bethesda, MD20892.E-mail:wardm1@mail.nih.gov. Submitted for publication December 16, 2014; accepted in revisedformJuly21,2015. 2 WARD ET ALand features suggestive of SpA but who do not meet the classificationcriteriaforAS. The goals of treatment of AS and nonradio

2015 American College of Rheumatology

8. Treatments for Fibromyalgia in Adult Subgroups

. Only two off-label pharmaceutical trials reported overall attrition of less than 25 percent. 64,65 Industry funded 85 percent of the 17 drug trials that reported the source of study funding. Industry study involvement included data management, statistical support, manuscript drafting, construction of tables, and study management. Corresponding and other authors in drug trials were often industry employees. Subgroup Outcomes In this section, we first examine the effect of drugs on various subgroups (...) (2 RCTs 3,58 and 1 pooled analysis 20 ) showed no difference among subgroups on the Patient Global Impression of Improvement (PGI- I). 76 For the PGI-I outcome, the duloxetine-by-MDD interaction was not statistically significant 20,58 or not reported. 3 The RCT by Russell et al. (2008) 3 displayed MDD subgroup data for the PGI-I. Study authors noted similar improvements in PGI-I in treated patients versus controls regardless of MDD status but did not report the interaction result. However

2015 Effective Health Care Program (AHRQ)

9. Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment

, such as the exclusion of some potential adverse events for alendronate or the possibility of lower compliance to treatment than they assumed. The study results might be relevant for other settings with similar relative prices and baseline fracture risk. Concluding remarks: The analysis considered a wide range of scenarios. The authors’ conclusions appear robust. Funding The study was supported by a grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, a grant from the National Center (...) of the two osteoporosis management strategies. A lifetime horizon was used. The perspective of the analysis was not explicitly reported. Effectiveness data: A selective approach appears to have been used to identify relevant sources of data. Treatment effect and rate of adverse events for alendronate were from clinical trials and meta-analyses. The baseline risk of fracture for the patient population was taken from the Study of Osteoporotic Fractures (SOF; an observational study). Other epidemiological

Full Text available with Trip Pro

2013 NHS Economic Evaluation Database.

10. Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)

18, 2019 See Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Information provided by (Responsible Party): National Institutes of Health Clinical Center (CC) ( National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) ) Study Details Study Description Go to Brief Summary: Background: About half the people who have a hematopoietic stem cell transplant using donor cells get cGVHD. This is chronic graft versus host disease. Immune cells from (...) information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 Sponsors and Collaborators National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Investigators Layout table for investigator information Principal Investigator: Dominique C Pichard, M.D. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) More Information Go to Additional Information: Publications: Layout table for additonal information

2018 Clinical Trials

11. Calcitriol Monotherapy for X-Linked Hypophosphatemia

: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Information provided by (Responsible Party): Eva Liu, Massachusetts General Hospital Study Details Study Description Go to Brief Summary: Children and adults with XLH recruited will be treated with calcitriol alone (without phosphate supplementation) for one year, during which the calcitriol dose will be escalated during the first 3 months of therapy. The investigators hypothesize that treatment of adults and children (...) Contact: Marie Demay, MD 16177263273 Locations Layout table for location information United States, Massachusetts Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Eva Liu, MD 617-525-5412 Contact: Marie Demay, MD 6177263273 Sponsors and Collaborators Massachusetts General Hospital National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Investigators Layout table for investigator information Principal Investigator: Eva Liu, MD

2018 Clinical Trials

12. Responsiveness of the PROMIS, NDI and ODI Instruments in Patients with Spinal Disorders. (PubMed)

. Global rating of change questions relating to pain and function levels was also administered.Baseline scores were compared with follow-up scores at four different time-points from 3-months to 6-months and beyond. Patient demographics, mean scores, paired-sample t tests, Standardized Response Mean (SRM), and Effect Size (ES) were analyzed to determine instrument responsiveness. This project was funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National (...) Responsiveness of the PROMIS, NDI and ODI Instruments in Patients with Spinal Disorders. The Patient-Reported Outcomes Information System (PROMIS) instruments are an important advancement in the use of PROs, but need to be evaluated with longitudinal data to determine whether they are responsive to change in specific clinical populations.The purpose of this study was to assess the responsiveness of the PROMIS Physical Function (PF), PROMIS Pain Interference (PI), Neck Disability Index (NDI

2018 The Spine Journal

13. Reducing Fall Risks for Adults With Obesity

and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03558100 Recruitment Status : Enrolling by invitation First Posted : June 15, 2018 Last Update Posted : June 15, 2018 Sponsor: Boston University Charles River Campus Collaborator: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Information (...) ClinicalTrials.gov identifier (NCT number): NCT03558100 Sponsors and Collaborators Boston University Charles River Campus National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Investigators Layout table for investigator information Principal Investigator: Simone V Gill Boston University Charles River Campus More Information Go to Publications of Results: Layout table for additonal information Responsible Party: Simone V. Gill, Associate Professor, Boston University Charles River Campus

2018 Clinical Trials

14. Ibuprofen With or Without Acetaminophen for Low Back Pain

in this arm will also receive ibuprofen 600mg every 6 hours for 7 days and an educational intervention. Drug: Acetaminophen Acetaminophen 500-1000mg every 6 hours Drug: Ibuprofen 600 mg Ibuprofen 600mg every 6 hours Behavioral: Educational intervention Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases) Handout on Health: Back Pain information webpage (available at http (...) ://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Active Comparator: Placebo Placebo Participants in this arm will also receive ibuprofen 600mg every 6 hours for 7 days and an educational intervention. Drug: Ibuprofen 600 mg Ibuprofen 600mg every 6 hours Behavioral: Educational intervention Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases) Handout on Health: Back Pain

2018 Clinical Trials

15. AAV2/8-LSPhGAA in Late-Onset Pompe Disease

, PhD 919-684-2036 Locations Layout table for location information United States, North Carolina Duke University Recruiting Durham, North Carolina, United States, 27705 Contact: Edward Smith, MD Principal Investigator: Edward C Smith, MD Sponsors and Collaborators Actus Therapeutics, Inc. Duke University National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Investigators Layout table for investigator information Principal Investigator: Edward C Smith, MD Duke University More (...) of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Information provided by (Responsible Party): Actus Therapeutics, Inc. Study Details Study Description Go to Brief Summary: Open-label, ascending dose trial of AAV2/8-LSPhGAA administered intravenously. Condition or disease Intervention/treatment Phase Pompe Disease Biological: AAV2/8LSPhGAA Phase 1 Phase 2 Detailed Description: This study will be a prospective, open-label trial designed to objectively assess the safety and bioactivity of AAV2/8

2018 Clinical Trials

16. A mechanistic approach to pain management: Applying the biopsychosocial model to physical therapy

tendinopathy clinical practice guidelines). Her work is currently supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under the Career Development Award K99AR071517. About Laura Frey Law Frey Law~Laura Laura Frey Law, MPT, MS, PhD is an Associate Professor in the Department of Physical Therapy & Rehabilitation Science, Carver College of Medicine, at the University of Iowa. She received her PhD in Rehabilitation Science in 2004, and has (...) studied, the mechanisms underlying many other physical therapy treatments are still unclear. Figure 2. This diagram illustrates sites of action, based on currently available mechanistic data, for A) common physical therapy treatments and B) common pharmacological treatments on the five pain mechanisms It is worth noting that a mechanism-based approach has long been used by pharmacologists to maximize the therapeutic benefit of pain relieving medications (Figure 2B). As an example in patients

2018 Body in Mind blog

17. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis

No external funding for review; one reviewer supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases. Bibliographic details Lopez-Olivo MA, Tayar JH, Pollono EN, Cueto JP, Gonzales-Crespo MR, Fulton S, Suarez-Almazor ME. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012; 308(9): 898-908 Original Paper URL Indexing Status Subject indexing assigned by CRD MeSH Arthritis, Rheumatoid; Biological Therapy; Humans (...) for missing data. Data extraction was checked by two additional reviewers and discrepancies were resolved through consensus and adjudication. Methods of synthesis Random-effects meta-analyses were used to calculate pooled relative risks and Peto odds ratios with 95% confidence intervals. A 0.5 correction for zero events was used. The authors reported that statistical heterogeneity was formally assessed; it appeared that Ι² was used to quantify heterogeneity. Separate analyses were undertaken for each type

2012 DARE.

18. Sprains and strains

on expert opinion in the fact sheet What are sprains and strains? published by the US National Institute for Arthritis and Musculoskeletal and Skin Diseases [ ], the review article Safe exercise published by the American Academy of Orthopaedic Surgeons (AAOS) [ ], and pragmatism, as CKS did not identify strong evidence for these recommendations. A Cochrane systematic review (search date December 2008) of interventions for preventing hamstring injuries found insufficient evidence to draw conclusions (...) or obese — this can put pressure on the joints and muscles. Previous sprain or strain. [ ; ; ; ; ] Prevalence How common are sprains and strains? Sprains and strains are common, especially in people who frequently participate in sport and when there are . About 30–50% of musculoskeletal injuries that present in primary care are tendon and ligament injuries, with ankle injury being the most common in both athletes and sedentary people. CKS was unable to find specific UK incidence or prevalence data

2016 NICE Clinical Knowledge Summaries

19. An economic analysis of outcomes and complications of treating distal radius fractures in the elderly

’ conclusions seem appropriate, as they emphasise the uncertainty in the clinical evidence. Funding Supported by grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, USA. Bibliographic details Shauver MJ, Clapham PJ, Chung KC. An economic analysis of outcomes and complications of treating distal radius fractures in the elderly. Journal of Hand Surgery. American volume 2011; 36(12): 1912-1918.e3 PubMedID DOI Original Paper URL Other publications of related interest Diaz (...) : A decision tree was developed to synthesise the cost and outcome data from published sources. The authors did not report the study perspective. Effectiveness data: The clinical data were from a published systematic review (see Other Publications of Related Interest) and some studies published since the review. The key measures of clinical effectiveness were the probabilities of various complications with each of the treatment options (including carpal tunnel syndrome, malunion, chronic regional pain

2011 NHS Economic Evaluation Database.

20. Study of Anti-Malarials in Incomplete Lupus Erythematosus

Medical Center Collaborator: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Information provided by (Responsible Party): Nancy Olsen, Milton S. Hershey Medical Center Study Details Study Description Go to Brief Summary: This project is a multicenter, randomized, placebo-controlled, double-blind clinical trial that is designed to test whether treating patients who are at risk for development of lupus with hydroxychloroquine can slow accumulation of disease features (...) -9110 Contact: Azza Badr, MBBS 2146487219 Sub-Investigator: Benjamin F Chong, MD Sponsors and Collaborators Milton S. Hershey Medical Center National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Investigators Layout table for investigator information Principal Investigator: Nancy J Olsen, MD Penn State MS Hershey Medical Center Principal Investigator: David R Karp, MD PhD UT Southwestern Medical Center More Information Go to Publications automatically indexed to this study

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>